ReviewBiomedicines2022
Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics.Arthritis research & therapy · 2026Trial
- Body Mass Index Is Associated with the Immunometabolic Profile in Psoriatic Arthritis: Real-Life Data.Diseases (Basel, Switzerland) · 2026Article
- Multitechnological integration advances musculoskeletal regeneration: synergistic progress of organoids, 3D/4D bioprinting, single-cell omics and artificial intelligence.Frontiers in bioengineering and biotechnology · 2026Review
- Algorithms and tools for data-driven omics integration to achieve multilayer biological insights: a narrative review.Journal of translational medicine · 2025Review
- The Role of Artificial Intelligence in the Diagnosis and Management of Rheumatoid Arthritis.Medicina (Kaunas, Lithuania) · 2025Article
- Review
- Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.Children (Basel, Switzerland) · 2024Review
- Application of Clinical Blood Metabogram to Type 2 Diabetes Mellitus.Metabolites · 2024Article
- Investigating causal associations among gut microbiota, metabolites, and psoriatic arthritis: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Chronic Pelvic Pain, Vulvar Pain Disorders, and Proteomics Profiles: New Discoveries, New Hopes.Biomedicines · 2023Review
- Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities.RMD open · 2023Article
- Repetitive and compulsive behavior after Early-Life-Pain associated with reduced long-chain sphingolipid species.Cell & bioscience · 2023Article
- Clinical Blood Metabogram: Application to Overweight and Obese Patients.Metabolites · 2023Article
- Psoriatic Arthritis: Pathogenesis and Targeted Therapies.International journal of molecular sciences · 2023Review
- Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.Frontiers in medicine · 2023Article
- Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.Therapeutic advances in musculoskeletal disease · 2023Review
- Current State and Future Perspectives on Personalized Metabolomics.Metabolites · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.